---
title: Treatment-free remission after a second TKI discontinuation attempt in patients
  with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the
  DAstop2 trial
date: '2024-01-26'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38278960/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240127170650&v=2.18.0
source: heidelberg[Affiliation]
description: 'Tyrosine kinase inhibitor (TKI) discontinuation in chronic myeloid leukemia
  (CML) has become part of routine care for patients with a sustained deep molecular
  response (DMR). Approximately 50% experience a molecular relapse upon TKI cessation.
  Most of them quickly regain DMR upon TKI resumption. Whether these patients can
  achieve a second treatment-free remission (TFR) remains unclear. DAstop2 (ClinicalTrials.gov
  ID: NCT03573596) is a prospective study including patients with a failed first ...'
disable_comments: true
---
Tyrosine kinase inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML) has become part of routine care for patients with a sustained deep molecular response (DMR). Approximately 50% experience a molecular relapse upon TKI cessation. Most of them quickly regain DMR upon TKI resumption. Whether these patients can achieve a second treatment-free remission (TFR) remains unclear. DAstop2 (ClinicalTrials.gov ID: NCT03573596) is a prospective study including patients with a failed first ...